The Duke Cancer Institute has announced new leadership appointments in support of the institute’s continued excellence and innovation.

Carey Anders, MD, has assumed the role of associate director of clinical research, succeeding Tom Stinchcombe, MD. Anders, a clinician-scientist with expertise in brain metastases, particularly from breast cancer, currently serves as co-director of the DCI Brain and Spine Metastases Program. Her research focuses on the genetic and genomic underpinnings of this condition, aiming to translate findings into effective treatment strategies.

Beginning in October 2024, April Salama, MD, assumed the newly created position of CTO medical director, collaborating with Anders in the leadership of the Oncology Clinical Research Unit (CRU). With a distinguished career in clinical trials and as the leader of the Melanoma Disease Group within Medical Oncology, Salama brings extensive expertise in combined modality therapy and innovative immunotherapies.

Alexandra Thomas, MD, FACP, has taken over as associate director of translational research, succeeding Donald McDonnell, PhD. Thomas, a breast medical oncologist, brings her research interests in cardiac effects of novel cancer therapies and treatment approaches for rare breast cancer subtypes. McDonnell transitioned to assistant director, leveraging his extensive translational research experience to collaborate with Thomas.

Emily Norboge, MPSA, succeeded Warren Kibbe, PhD, as the DCI's chief research informatics officer (previously Chief Data Officer. Norboge brings significant expertise in informatics and a keen interest in integrating artificial intelligence into clinical research. She also co-chairs the Shared Resource Oversight Committee alongside Christopher Counter, PhD.